|
|
|
| Effects of Zoledronic Acid on the Expression of VEGF-C and COX2 in Patients with Advanced Non-small Cell Lung Cancer |
| WANG Wei |
| Department of Blood Oncology ,PLA 101st Hospital,214000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical effects of zoledronic acid in patients with advanced non-small cell lung cancer(NSCLC) and its effects on the levels of vascular endothelial growth factor C (VEGF-C) and cyclooxygenase 2 (COX2). 【Methods】Sixty-eight patients with advanced NSCLC cancer with bone metastases were divided into two groups (n=34 in each group). Patients in the control group received routine TP chemotherapy, while patients in the observation group received zoledronic acid in addition to TP chemotherapy. The clinical effects were compared between the two groups. The expression levels of VEGF-C, COX2 , BLAP (the specific sequence of bone alkaline phosphatase) , PINP (type I procollagen N-terminal propeptide) β -CTX (type I collagen carboxy terminal peptide β) and β-crosslaps before and after treatment were also compared between the two groups. 【Results】The therapeutic effect rate of the observation group was 94.12% (32/34), which was higher than that of the control group (79.41%, 27/34) (P<0.05). The levels of BLAP, PINP, β-CTX, β-crosslaps, VEGF-C and COX2 in the observation group were lower than those in the control group(P<0.05). The incidence of rash, muscle , joint pain, myelosuppression, arrhythmia, kidney dysfunction, headache and fever in both groups was not statistically significant difference (P>0.05). 【Conclusion】The use of zoledronic acid in patients with advanced NSCLC bone metastasis can improve the biochemical markers of bone turnover, reduce the levels of VEGF-C and COX2, and have high drug safety. It is worthy of popularization and application.
|
|
Received: 17 September 2018
|
|
|
|
|
|
[1] Wang W, Song Z, Zhang Y, et al. P3.02b-093 zoledronic acid enhances the effects of icotinib on non-small cell lung cancer patients with bone metastases[J]. J Thorac Oncol, 2017, 12(1):S1248.
[2] 王俊斌,杨燕,汪子书,等.长春瑞滨或吉西他滨联合顺铂治疗转移性三阴性乳腺癌的临床疗效与安全性评价[J].中国临床药理学杂志,2016,32(1):24-26.
[3] 虞晓林,申泓.唑来膦酸联合化疗治疗非小细胞肺癌骨转移的疗效观察[J].实用临床医药杂志,2016,20(11):156-158.
[4] 梁研,郭进华.唑来膦酸联合化疗治疗非小细胞肺癌骨转移效果观察[J].肿瘤研究与临床,2016,28(5):345-347.
[5] Moos R V, Body J J, Egerdie B, et al. Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases[J]. Support Care Cancer, 2016, 24(3):1327.
[6] 曾少容,凌钦杰,曾维亮.唑来膦酸联合放射治疗对非小细胞肺癌骨转移患者癌痛的疗效观察[J].临床肿瘤学杂志,2017,22(2):152-156.
[7] 邱慧兵,易铁男,张凌云,等.唑来膦酸联合放疗与联合化疗治疗非小细胞肺癌骨转移效果观察[J].肿瘤研究与临床,2017,29(7):437-441.
[8] 陈晓华,龚惠莉,邱晓平.唑来膦酸联合吉西他滨治疗非小细胞肺癌疗效观察[J].海南医学,2017,28(11):1744-1746. |
|
|
|
2019, Vol. 36 
